EARNINGS ROUND-UP: ILMN, SYK, TMO, VAR
This article was originally published in Clinica
Executive Summary
Genome sequencing specialist Illumina’s share price jumped after it posted 27% sales growth during its first fiscal quarter. Its stock closed up 5% at $147.98 on 22 April, the day it reported the results, and climbed another 4% to close at $153.69 the following day. Its share price hit an all-time high of $179.65 in February, making a mockery of Roche’s $51 per share offer in 2012. Illumina has increased its guidance for full-year 2014 and is now predicting 21-23% revenue growth (from 15-17% previously) and non-GAAP earnings of $2.10-2.15 per diluted share (from $2.00-2.06).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.